Who Paid My Doc
Aviva Zigman
General Practice Milwaukie, OR Medical Doctor
NPI 1013970060 CMS profile 534594
4560 Se International Way Ste 100, Milwaukie, OR 97222
General payments
$437
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Aviva Zigman of Milwaukie, OR is reported in the CMS Open Payments database as having received $437 across 10 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 66th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $37 | 2 | |
| 2022 | General | $277 | 4 | |
| 2021 | General | $123 | 4 |
Beside peers
- Aviva Zigman
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Aviva Zigman were reported at $37. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Aviva Zigman | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $107 | $37–$285 | $163 |
| 2020 | $0 | $75 | $25–$213 | $114 |
| 2021 | $123 | $93 | $30–$272 | $132 |
| 2022 | $277 | $103 | $36–$279 | $149 |
| 2023 | $0 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $37 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 49 drugsPart D claims
1,577
Drug cost
$82,196
Branded share of claims
13.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 84 | $25,673 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 12 | $8,404 | |
| Atorvastatin Calcium | Generic | 120 | $4,149 | |
| Xarelto Rivaroxaban | Brand | 12 | $3,428 | |
| Jardiance Empagliflozin | Brand | 11 | $3,414 | |
| Divalproex Sodium | Generic | 13 | $2,812 | |
| Risperidone | Generic | 20 | $2,360 | |
| Memantine Hcl | Generic | 33 | $2,067 | |
| Tamsulosin Hcl | Generic | 59 | $1,813 | |
| Duloxetine Hcl | Generic | 41 | $1,810 |
The 10 drugs with the highest cost, of 49 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 7 billing codesPaid by Medicare
$11,128
Medicare patients
80
Services billed
100
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Heart failure | 51% | |
| Arthritis | 50% | |
| Alzheimer's or dementia | 46% | |
| Chronic kidney disease | 44% | |
| Atrial fibrillation | 43% | |
| Depression | 41% | |
| Diabetes | 39% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
10 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.